Влияние качества биомаркеров на эффективность скрининга 1 го триместра

Embed Size (px)

Citation preview

  • The world leader in serving science Proprietary & Confidential

    ,

    , 2015

    -

  • 2 Proprietary & Confidential

    =

    (a priori)

    X

    ( ) )

    = a priori x LR1* x LR2 x LR3

    LR= likelihood ratio - -

  • 3 Proprietary & Confidential

    .

  • 4 Proprietary & Confidential

  • 5 Proprietary & Confidential

    1. =

    2.

    3.

    4.

    KRYPTOR

  • 6 Proprietary & Confidential

    1100 68 ,

    .

    PAPP-A

    Old 4267 mU/L 254 4,4%

    Level J 3761 mU/L 1047 3,5%

    Level N 1082 mU/L 1158 3,5%

    Level C 112 mU/L 1185 4,4%

  • 7 Proprietary & Confidential

    1100 68 ,

    .

    Free

    Old 37,4 ng/mL 288 3,3%

    Level L 106 ng/mL 1104 3,2%

    Level D 16,7 ng/mL 1201 3,1%

    Level C 5,1 ng/mL 1203 3,9%

  • 8 Proprietary & Confidential

    UK NEQAS

    UK NEQAS

    - UK NEQAS

    UK

  • 9 Proprietary & Confidential

    - UK NEQAS

  • 10 Proprietary & Confidential

    2003- 2015 = 3.0%

    UK NEQAS: Free

    Feb 2003-Feb 2015

  • 11 Proprietary & Confidential

    2003- 2015 = 3.1%

    UK NEQAS: PAPP-A

    Feb 2003-Feb 2015

  • 12 Proprietary & Confidential

    DSNEWS 10(1): 30-31

  • 13 Proprietary & Confidential

    UK NEQAS: PAPP-A

    2003 2014: KRYPTOR BIAS 0.1% (-0.4 0.6%)

  • 14 Proprietary & Confidential

    UK NEQAS -

    KRYPTOR BIAS PAPP-A Free

  • 15 Proprietary & Confidential

    -

  • 16 Proprietary & Confidential

    UK NEQAS

  • 17 Proprietary & Confidential

    PAPP-A

    -

    KRYPTOR

    PAPP-A

  • 18 Proprietary & Confidential

    BRAHMS: UK NEQAS!

    !

    BRAHMS KRYPTOR

    FMF 1999